This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: September 10, 2010
Last updated: August 15, 2016
Last verified: August 2016
The purpose of this study is to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program. This study will combine all currently ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned studies into one single long-term extension protocol that will provide patients with continuous treatment and will continue until fingolimod is registered, commercially available, and reimbursed in the respective countries.

Condition Intervention Phase
Relapsing Forms of Multiple Sclerosis Drug: FTY720 Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Long-term safety & tolerability of fingolimod 0.5 mg/day in patients with relapsing forms of MS [ Time Frame: up to 4 years ]

Secondary Outcome Measures:
  • Long-term efficacy of fingolimod 0.5 mg/day in patients with relapsing forms of MS [ Time Frame: up to 4 years ]

Enrollment: 4126
Study Start Date: September 2010
Estimated Study Completion Date: October 2018
Estimated Primary Completion Date: October 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fingolimod 0.5 mg/day Drug: FTY720


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who have completed selected ongoing or planned trials with FTY720.

Exclusion Criteria:

  • Premature permanent discontinuation of a previous fingolimod study.
  • Pregnant or nursing (lactating) women.
  • Women of child-bearing potential, UNLESS they are using two birth control methods, at least 1 of which must be hormonal contraception, tubal sterilization, partner's vasectomy or intrauterine device.
  • Chronic disease of the immune system, other than multiple sclerosis, which may require immunosuppressive treatment.
  • Diabetic patients with moderate or severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and uncontrolled diabetic patients with HbA1c > 8%.
  • Active systemic bacterial, viral or fungal infections, or known to have AIDS, Hepatitis B, Hepatitis C infection or have positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.
  • Previous treatment with cladribine, cyclophosphamide or mitoxantrone.
  • Treatment with immunoglobulins and/or monoclonal antibodies (including Natalizumab) in the past 3 months during the previous fingolimod study:
  • Any of the following cardiovascular conditions that have developed during the previous fingolimod study:

    • Myocardial infarction within the past 6 months prior to entry in the extension study or with current unstable ischemic heart disease;
    • Cardiac failure (Class III, according to New York Heart Association Classification) or any severe cardiac disease as determined by the investigator;
    • Arrhythmia requiring current treatment with Class III antiarrhythmic drugs (e.g., amiodarone, bretylium, sotalol, ibutilide, azimilide, dofetilide)
    • History or presence of a third degree AV block
    • Proven history of sick sinus syndrome or sino-atrial heart block
    • Known history of angina pectoris due to coronary spasm or Raynaud's phenomenon
  • Any of the following pulmonary conditions during the previous fingolimod study:

    • Severe respiratory disease or pulmonary fibrosis diagnosed (during the previous fingolimod study)
    • Active tuberculosis
  • Alcohol abuse, chronic liver disease during the previous fingolimod study.

The patient must have participated in a previous fingolimod trial to be eligible to participate in this trial.

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01201356

  Show 458 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT01201356     History of Changes
Other Study ID Numbers: CFTY720D2399
2010-020515-37 ( EudraCT Number )
Study First Received: September 10, 2010
Last Updated: August 15, 2016

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Relapsing forms of MS
Multiple Sclerosis

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Fingolimod Hydrochloride
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on September 19, 2017